NDC 84612-066 – Wezlana
Ustekinumab 130 mg/26mL · Injection, Solution · Intravenous
Product NDC84612-066
Product details
- Brand name
- Wezlana
- Generic name
- Ustekinumab-auub
- Labeler
- Nuvaila Limited
- Dosage form
- Injection, Solution
- Route
- Intravenous
- Marketing category
- BLA · BLA761331
- Marketed since
- January 1, 2025
- Listing expires
- December 31, 2027
- Pharmacologic class
- Interleukin-12 Antagonist; Interleukin-23 Antagonist
Active ingredients
- Ustekinumab 130 mg/26mL
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 84612-066-01 | 1 VIAL in 1 CARTON (84612-066-01) / 26 mL in 1 VIAL | Jan 1, 2025 |
Other Wezlana products
- 84612-055 Ustekinumab 45 mg/.5mL · Injection, Solution · Nuvaila Limited
- 84612-076 Ustekinumab 45 mg/.5mL · Injection, Solution · Nuvaila Limited
- 84612-089 Ustekinumab 90 mg/mL · Injection, Solution · Nuvaila Limited
- 84612-855 Ustekinumab 45 mg/.5mL · Injection, Solution · Nuvaila Limited
- 84612-876 Ustekinumab 45 mg/.5mL · Injection, Solution · Nuvaila Limited
- 84612-889 Ustekinumab 90 mg/mL · Injection, Solution · Nuvaila Limited